BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$1.35, compared with -$0.94 a year earlier. Trailing-twelve-month EPS (Basic) was -$5.71.
Context
- EPS (Basic) increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 6 analysts of -$2.24 (+47.9%) for the fiscal year ending Dec 2026, a step up from the -1034.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.35-8.0% QoQ
- Last fiscal yearDec 2025
- -$4.3-1034.8% YoY
- LTMMar 2026
- -$5.71-289.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -43.6% | +55.2% | +98.8 pp |
| 1 year | -1034.8% | +47.9% | +1082.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (4.30) USD
- Year-over-year change
- -1034.8%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.30) | -1034.8% |
| FY2024 | 2024-12-31 | 0.46 | +114.6% |
| FY2023 | 2023-12-31 | (3.16) | -1580100.0% |
| FY2022 | 2022-12-31 | 0.00 | +109.5% |
| FY2021 | 2021-12-31 | (0.00) | — |
EPS (Basic) vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -289.5% is the lowest of 10, against a peer median of +14.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Aug 2026 | $2.51 USD | +184.5% | — | |
| LTM Mar 2026 | -$0.85 USD | +82.7% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$1.29 USD | +14.6% | — |
| LTM Sep 2026 | -$1.38 USD | -51.6% | — | |
| LTM Mar 2026 | -CHF 1.73 CHF | +27.0% | — | |
| LTM Mar 2026 | -$2.12 USD | +59.5% | — | |
| LTM Jun 2026 | -$2.17 USD | +13.5% | — | |
| LTM Mar 2026 | -$2.75 USD | +13.5% | — | |
| LTM Sep 2026 | -$4.08 USD | +1.0% | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | -$5.71 USD | -289.5% | — |
| Peer median (excluding BBOT) | — | +14.6% | — | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| Weighted Avg Shares | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
| Weighted Avg Shares (Diluted) | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.